A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Children and Adolescents From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis
Bristol-Myers Squibb
60 participants
Mar 13, 2025
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.
Eligibility
Inclusion Criteria3
- Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA).
- Participants must have at least three joints that are affected by arthritis.
- Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems.
Exclusion Criteria3
- Participants must not have been diagnosed with JPsA before 5 years of age.
- Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA,
- Participants must not have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Specified dose on specified days
Specified dose on specified days
Locations(47)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06869551